ArticleFrontiers in oncology2025
Antitumor efficacy of 5-aminolevulinic acid (5-ALA)-based radiodynamic therapy under single-dose X-ray irradiation in colon cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: 5-Aminolevulinic acid (5-ALA)-based radiodynamic therapy (RDT), an experimental approach that combines systemic administration of 5-ALA with ionizing radiation, has demonstrated antitumor efficacy primarily in preclinical studies using fractionated irradiation protocols. In recent years, single-dose and hypofractionated irradiation regimens have been increasingly adopted in clinical radiotherapy; however, the therapeutic potential of 5-ALA-based RDT under single-dose irradiation conditions remains to be elucidated. Methods: We evaluated the accumulation of protoporphyrin IX (PpIX) in human colon cancer HT-29 cells compared with previously studied cell lines, mouse melanoma B16/BL6 and human glioblastoma U-251 MG, U-87 MG Results: HT-29 cells exhibited equal or greater PpIX accumulation compared with other tumor cell lines. Conclusion: This study demonstrates for the first time that 5-ALA combined with single-dose X-ray irradiation exerts a strong antitumor effect on HT-29 xenografts. The observed effects may be mediated by induction of immunogenic cell death, modulation of the tumor microenvironment, and suppression of tumor cell survival pathways. These findings highlight single-dose 5-ALA-based RDT as a potential novel therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.